ROCKVILLE, Md., Feb. 4, 2014 /PRNewswire/ -- Synthetic Biologics,
Inc. (NYSE MKT: SYN), a developer of product candidates focused on
the prevention and treatment of serious infectious and other
diseases, announced today that Jeffrey
Riley, CEO, is scheduled to present at the BIO CEO &
Investor Conference on Monday, February 10,
2014, at 10:00 a.m. (ET) at
the Waldorf Astoria (Duke of Windsor
room) in New York.
A live webcast of Synthetic Biologics' presentation may be
accessed by logging onto the internet at
http://www.veracast.com/webcasts/bio/ceoinvestor2014/98124275805.cfm.
After the presentation, a replay will be archived and accessible
for 30 days at the same website.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology
company focused on the development of product candidates for
serious infectious and other diseases. Synthetic Biologics is
developing oral treatments targeting archaea, a non-bacterial
intestinal form of life increasingly associated with chronic
diseases such as irritable bowel syndrome (IBS), obesity and type 2
diabetes, an oral biologic to protect the gastrointestinal
microflora from the effects of IV antibiotics for the prevention of
C. diff infection, a series of monoclonal antibodies (mAbs)
for the treatment of Pertussis and Acinetobacter infections,
and a biologic targeted at the prevention and treatment of IBS. In
addition, the Company is developing an oral estriol drug candidate
for the treatment of relapsing-remitting multiple sclerosis (MS)
and cognitive dysfunction in MS (with results of an ongoing 164
subject, 15 center, two-year, double blind, placebo controlled,
Phase II relapsing-remitting MS clinical trial expected to be
announced during the first half of 2014). For more information,
please visit Synthetic Biologics' website at
www.syntheticbiologics.com.
SOURCE Synthetic Biologics, Inc.